Is atrial fibrillation an inflammatory disorder?

There is mounting evidence to support the influence of inflammation in the pathogenesis of atrial fibrillation (AF). Indeed, AF is associated with increased levels of known inflammatory markers, even after adjustment for confounding factors. The renin-angiotensin-aldosterone system (RAAS) appears to play a key role in this process. Atrial biopsies from patients with AF have also confirmed the presence of inflammation. Furthermore, there is preliminary evidence to support a number of drug therapies that have the potential to reduce the clinical burden of AF. In this review, we present an overview of the evidence supporting a link between inflammation and AF, and some of the drug therapies, such as the angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, steroids, fish oils, and vitamin C, that might be efficacious in the prevention of AF by modulating inflammatory pathways.

[1]  E. Watanabe,et al.  High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. , 2006, International journal of cardiology.

[2]  C. Navarrete,et al.  C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia". , 2006, International journal of cardiology.

[3]  G. Lip,et al.  Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. , 2006, Journal of the American College of Cardiology.

[4]  A. Waldo.  Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study , 2006 .

[5]  J. Svendsen,et al.  Inflammation in the genesis and perpetuation of atrial fibrillation. , 2005, European heart journal.

[6]  G. Lip,et al.  The role of inflammation in atrial fibrillation , 2005, International journal of clinical practice.

[7]  J. Goudevenos,et al.  Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? , 2005, International journal of clinical practice.

[8]  J. Goudevenos,et al.  Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. , 2005, International journal of cardiology.

[9]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[10]  C. Pandozi,et al.  N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. , 2005, Journal of the American College of Cardiology.

[11]  U. Das.  Is angiotensin-II an endogenous pro-inflammatory molecule? , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[12]  J. Langberg,et al.  Lipid-lowering therapy reduces the prevalence of atrial fibrillation , 2005 .

[13]  G. Yi,et al.  Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[14]  G. Lip,et al.  Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. , 2005, The American journal of cardiology.

[15]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[16]  Å. Sjöholm,et al.  Endothelial inflammation in insulin resistance , 2005, The Lancet.

[17]  K. Dickstein,et al.  Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. , 2005, European heart journal.

[18]  M. P. van den Berg,et al.  C-reactive protein and microalbuminuria are associated with atrial fibrillation. , 2005, International journal of cardiology.

[19]  S. Devaraj,et al.  Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role , 2005, Current opinion in nephrology and hypertension.

[20]  R. Kronmal,et al.  Relation of Elevated C-Reactive Protein and Interleukin-6 Levels to Left Atrial Size and Duration of Episodes in Patients With Atrial Fibrillation , 2005 .

[21]  P. Elton,et al.  Is there a role for long-chain omega3 or oil-rich fish in the treatment of atrial fibrillation? , 2005, Medical hypotheses.

[22]  J. Rutledge,et al.  Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. , 2005, Atherosclerosis.

[23]  P. Vestergaard,et al.  n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. , 2005, The American journal of clinical nutrition.

[24]  I. Kubota,et al.  C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation , 2005, Heart and Vessels.

[25]  G. Lip,et al.  Novel therapies for the prevention of stroke , 2004, Expert opinion on investigational drugs.

[26]  B. Horne,et al.  Frequency of elevation of C-reactive protein in atrial fibrillation. , 2004, The American journal of cardiology.

[27]  B. O'brien,et al.  Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation , 2004, Annals of Internal Medicine.

[28]  G. Lip,et al.  Endothelial dysfunction: methods of assessment and application to hypertension. , 2004, Current pharmaceutical design.

[29]  Stanley Nattel,et al.  Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs , 2004, Circulation.

[30]  G. Lip,et al.  Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation , 2004, Heart.

[31]  Claudia Stöllberger,et al.  Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. , 2004, European heart journal.

[32]  A. Yıldırır,et al.  Non-lipid effects of statins: emerging new indications. , 2004, Current vascular pharmacology.

[33]  R. D. Murray,et al.  Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. , 2004, The American journal of cardiology.

[34]  Ashok K. Chaudhary,et al.  Oxidized Omega-3 Fatty Acids Inhibit NF-&kgr;B Activation Via a PPAR&agr;-Dependent Pathway , 2004 .

[35]  G. Lip,et al.  Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. , 2004, American heart journal.

[36]  Jian Peng,et al.  Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[37]  H. Crijns,et al.  Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. , 2004, European heart journal.

[38]  G. Lip,et al.  Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. , 2004, Journal of molecular and cellular cardiology.

[39]  E. Minar,et al.  Angiotensin Receptor Blockade Decreases Markers of Vascular Inflammation , 2004, Journal of cardiovascular pharmacology.

[40]  A. John Camm,et al.  Atrial fibrillation and heart failure: natural history and pharmacological treatment. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[41]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[42]  D. Fliser,et al.  Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation , 2004, Circulation.

[43]  G. Lip,et al.  Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. , 2004, The American journal of cardiology.

[44]  A. Torbicki,et al.  Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. , 2004, Chest.

[45]  L. Mascitelli,et al.  Cardiovascular protections in severely impaired hemostasis. , 2004, Circulation.

[46]  Bruce M Psaty,et al.  Fish intake and risk of incident atrial fibrillation. , 2004, Circulation.

[47]  H. Drexler,et al.  Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. , 2004, Journal of the American College of Cardiology.

[48]  J. Panés,et al.  Direct evidence of leukocyte adhesion in arterioles by angiotensin II. , 2004, Blood.

[49]  J. Dernellis,et al.  Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.

[50]  P. Modesti,et al.  Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component , 2004, Circulation research.

[51]  JeanDavignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004 .

[52]  G. Lip,et al.  Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[53]  A. Takeshita,et al.  Critical Role of Monocyte Chemoattractant Protein-1 Receptor CCR2 on Monocytes in Hypertension-Induced Vascular Inflammation and Remodeling , 2004, Circulation research.

[54]  D. Pimentel,et al.  Angiotensin II Differentially Regulates Interleukin-1-β-inducible NO Synthase (iNOS) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression , 2004, Journal of Biological Chemistry.

[55]  T. Horinouchi,et al.  C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? , 2004, Japanese Heart Journal.

[56]  T. Unger,et al.  Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme , 2004, Expert opinion on pharmacotherapy.

[57]  M. Chung,et al.  Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. , 2004, The American journal of cardiology.

[58]  Marylyn D Ritchie,et al.  Renin-Angiotensin System Gene Polymorphisms and Atrial Fibrillation , 2004, Circulation.

[59]  R. Muraro,et al.  Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2–Dependent Matrix Metalloproteinase Activity , 2004, Circulation.

[60]  A. Tveit,et al.  Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. , 2004, The American journal of cardiology.

[61]  G Hindricks,et al.  Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease , 2004, Heart.

[62]  M. Pfeffer,et al.  1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM , 2004 .

[63]  D G Beevers,et al.  The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? , 2004, Journal of Human Hypertension.

[64]  TatsuhikoSudo,et al.  Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression , 2004 .

[65]  Deepak L. Bhatt,et al.  Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers , 2004, Current opinion in rheumatology.

[66]  K. Saku,et al.  The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. , 2003, Cardiovascular research.

[67]  W. Leifert,et al.  Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids , 2000, Molecular and Cellular Biochemistry.

[68]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[69]  Ashok K. Chaudhary,et al.  Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[70]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[71]  R. Goldberg,et al.  Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. , 2003, The American journal of cardiology.

[72]  C. Boos,et al.  Rate or rhythm control in persistent atrial fibrillation? , 2003, QJM : monthly journal of the Association of Physicians.

[73]  C. Lau,et al.  Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. , 2003, The American journal of cardiology.

[74]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[75]  A. Blann.  Assessment of Endothelial Dysfunction: Focus on Atherothrombotic Disease , 2003, Pathophysiology of Haemostasis and Thrombosis.

[76]  G. Hindricks,et al.  Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. , 2003, Journal of the American College of Cardiology.

[77]  S. Nattel,et al.  Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. , 2003, Cardiovascular research.

[78]  C. Zincarelli,et al.  Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease , 2003, Vascular medicine.

[79]  S. Verma,et al.  New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.

[80]  Francesco Burzotta,et al.  The −174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation. Is Atrial Fibrillation an Inflammatory Complication? , 2003, Circulation.

[81]  S. Connolly,et al.  Combined Antiplatelet Therapy in Atrial Fibrillation: , 2003 .

[82]  G. Mensah,et al.  Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention , 2003, Circulation.

[83]  S. Hohnloser,et al.  Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. , 2003, European heart journal.

[84]  E. Rimm,et al.  Habitual Dietary Intake of n-3 and n-6 Fatty Acids in Relation to Inflammatory Markers Among US Men and Women , 2003, Circulation.

[85]  G. Lip,et al.  Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. , 2003, European heart journal.

[86]  James B Seward,et al.  The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. , 2003, Journal of the American College of Cardiology.

[87]  C. Boos,et al.  Persistent atrial fibrillation: rate control or rhythm control , 2003, BMJ : British Medical Journal.

[88]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[89]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[90]  M. Levrero,et al.  Endothelial activation by angiotensin II through NFκB and p38 pathways: Involvement of NFκB‐inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin , 2003, Journal of cellular physiology.

[91]  J. Egido,et al.  Inflammation and angiotensin II. , 2003, The international journal of biochemistry & cell biology.

[92]  Sander Verheule,et al.  Alterations in Atrial Electrophysiology and Tissue Structure in a Canine Model of Chronic Atrial Dilatation Due to Mitral Regurgitation , 2003, Circulation.

[93]  U. Tebbe,et al.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. , 2003, Journal of the American College of Cardiology.

[94]  D. Newby,et al.  Intra-Arterial Tumor Necrosis Factor-&agr; Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[95]  P. Ridker,et al.  C-reactive protein and other inflammatory risk markers in acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[96]  A. Michelucci,et al.  Angiotensin‐Converting Enzyme and Endothelial Nitric Oxide Synthase Polymorphisms in Patients with Atrial Fibrillation , 2003, Pacing and clinical electrophysiology : PACE.

[97]  S. Connolly,et al.  Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. , 2003, Journal of cardiovascular electrophysiology.

[98]  T. Ohe,et al.  Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. , 2003, Thrombosis research.

[99]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[100]  B. Greenberg,et al.  Molecular Medicine Tumor Necrosis Factor-�–Induced AT 1 Receptor Upregulation Enhances Angiotensin II–Mediated Cardiac Fibroblast Responses That Favor Fibrosis , 2022 .

[101]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[102]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[103]  M. Trip,et al.  Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. , 2002, Atherosclerosis.

[104]  Marta Ruiz-Ortega,et al.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. , 2002, Kidney international. Supplement.

[105]  J. Rutledge,et al.  Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. , 2002, Physiological genomics.

[106]  G. Lip,et al.  A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[107]  Kathleen M. Weil,et al.  Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction , 2002, Circulation.

[108]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[109]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[110]  B. Lévy,et al.  Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways , 2002, Laboratory Investigation.

[111]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[112]  Zoltan Szalay,et al.  Structural correlate of atrial fibrillation in human patients. , 2002, Cardiovascular research.

[113]  M. Allessie,et al.  Electrical, contractile and structural remodeling during atrial fibrillation. , 2002, Cardiovascular research.

[114]  L. Tavazzi,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002 .

[115]  M. Santini,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002, Circulation.

[116]  J. Manson,et al.  Blood levels of long-chain n-3 fatty acids and the risk of sudden death. , 2002, The New England journal of medicine.

[117]  J. Nakura,et al.  Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy , 2002, Journal of Human Genetics.

[118]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[119]  S. Nattel.  New ideas about atrial fibrillation 50 years on , 2002, Nature.

[120]  S. Olsson,et al.  Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique , 2002, Clinical physiology and functional imaging.

[121]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[122]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[123]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[124]  J. Dernellis,et al.  C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation , 2001, Acta cardiologica.

[125]  S. Nattel,et al.  Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure , 2001, Circulation.

[126]  P. Ridker,et al.  Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .

[127]  A. Maggioni,et al.  Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data , 2001, Heart.

[128]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[129]  Y Rudy,et al.  Mechanistic Insights Into Very Slow Conduction in Branching Cardiac Tissue: A Model Study , 2001, Circulation research.

[130]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[131]  P. Sandercock,et al.  Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial , 2001, Stroke.

[132]  M. Chung,et al.  Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation , 2001, Circulation research.

[133]  G. Lip,et al.  Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. , 2001, European heart journal.

[134]  A. Gotto,et al.  Pleiotropic effects of statins: do they matter? , 2001, Current opinion in lipidology.

[135]  D. V. Van Wagoner,et al.  Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation , 2001, Circulation.

[136]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[137]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial , 2001 .

[138]  L. Badimón,et al.  3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Prevents Endothelial NO Synthase Downregulation by Atherogenic Levels of Native LDLs: Balance Between Transcriptional and Posttranscriptional Regulation , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[139]  U Schotten,et al.  Cellular Mechanisms of Depressed Atrial Contractility in Patients With Chronic Atrial Fibrillation , 2001, Circulation.

[140]  J. Manson,et al.  Types of Dietary Fat and Risk of Coronary Heart Disease: A Critical Review , 2001, Journal of the American College of Nutrition.

[141]  O. Carretero,et al.  Upregulated Expression of Rat Heart Intercellular Adhesion Molecule-1 in Angiotensin II– but Not Phenylephrine- Induced Hypertension , 2001, Hypertension.

[142]  M. Wolzt,et al.  Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia , 2001, Thrombosis and Haemostasis.

[143]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[144]  P. Vardas,et al.  Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence. , 2000, Cardiovascular research.

[145]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[146]  J. Farmer.  Pleiotropic effects of statins , 2000, Current atherosclerosis reports.

[147]  A. Goette,et al.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. , 2000, Journal of the American College of Cardiology.

[148]  N. Dali-Youcef,et al.  Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[149]  S. Fichtlscherer,et al.  Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels , 2000, Annals of medicine.

[150]  W. Connor,et al.  Importance of n-3 fatty acids in health and disease. , 2000, The American journal of clinical nutrition.

[151]  S. Boschi,et al.  Polyunsaturated fatty acids and inflammatory bowel disease. , 2000, The American journal of clinical nutrition.

[152]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.

[153]  R. Gibson,et al.  Dietary polyunsaturated fatty acids and inflammatory mediator production. , 2000, The American journal of clinical nutrition.

[154]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[155]  R W Alexander,et al.  Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. , 1999, Circulation.

[156]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[157]  P. Libby,et al.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[158]  L. Køber,et al.  The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. , 1999, European heart journal.

[159]  M. Yasuhara,et al.  Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. , 1999, Biochemical pharmacology.

[160]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[161]  M. Pfeffer,et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.

[162]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[163]  N. Kamiyama,et al.  Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. , 1998, Japanese circulation journal.

[164]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[165]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[166]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[167]  F. Paganelli,et al.  Antibodies Against Myosin in Sera of Patients with Idiopathic Paroxysmal Atrial Fibrillation , 1998, Journal of cardiovascular electrophysiology.

[168]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[169]  H. Tse,et al.  ELECTRICAL REMODELLING OF CHRONIC ATRIAL FIBRILLATION , 1997, Clinical and experimental pharmacology & physiology.

[170]  C. Hack,et al.  Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. , 1997, Circulation.

[171]  L. Cleland,et al.  Dietary n-3 fatty acids and therapy for rheumatoid arthritis. , 1997, Seminars in arthritis and rheumatism.

[172]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.

[173]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[174]  D. Galaris,et al.  On the molecular mechanism of metmyoglobin-catalyzed reduction of hydrogen peroxide by ascorbate. , 1997, Free radical biology & medicine.

[175]  N. Iwai,et al.  Assessment of the angiotensin II-forming pathway in human atria. , 1997, Heart and vessels.

[176]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[177]  P. Erne,et al.  Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. , 1996, European heart journal.

[178]  H. Crijns,et al.  Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. , 1995, Journal of cardiac failure.

[179]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[180]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[181]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[182]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[183]  J Clémenty,et al.  Radiofrequency Catheter Ablation in Unusual Mechanisms of Atrial Fibrillation: , 1994, Journal of cardiovascular electrophysiology.

[184]  J. Cleland,et al.  Co‐expression of renin—angiotensin system component genes in human atrial tissue , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[185]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[186]  M. Paul,et al.  Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. , 1993, The Journal of clinical investigation.

[187]  A. di Lenarda,et al.  Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. , 1992, American heart journal.

[188]  M. Fishbein,et al.  Detection and localization of tumor necrosis factor in human atheroma. , 1990, The American journal of cardiology.

[189]  P. Libby,et al.  Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. , 1989, Journal of immunology.

[190]  M. Spach,et al.  Relating Extracellular Potentials and Their Derivatives to Anisotropic Propagation at a Microscopic Level in Human Cardiac Muscle: Evidence for Electrical Uncoupling of Side‐to‐Side Fiber Connections with Increasing Age , 1986, Circulation research.

[191]  K. Wirtz,et al.  Interaction of C-reactive protein with artificial phosphatidylcholine bilayers , 1979, Nature.

[192]  K. Shimada,et al.  Binding sites for angiotensin II in human mononuclear leucocytes. , 1978, Journal of biochemistry.

[193]  D. Spodick.  Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. , 1976, JAMA.

[194]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.